Cargando…

Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma

SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Kai, Wang, Youpeng, Zhang, Yuanzheng, Sun, Hongfa, Zhang, Xuhui, Sun, Chuandong, Zhang, Bingyuan, Zhang, Ying, Cheng, Haoyue, Liu, Ao, Wang, Mengyao, Han, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600135/
https://www.ncbi.nlm.nih.gov/pubmed/36291846
http://dx.doi.org/10.3390/cancers14205062
_version_ 1784816766075011072
author Ma, Kai
Wang, Youpeng
Zhang, Yuanzheng
Sun, Hongfa
Zhang, Xuhui
Sun, Chuandong
Zhang, Bingyuan
Zhang, Ying
Cheng, Haoyue
Liu, Ao
Wang, Mengyao
Han, Bing
author_facet Ma, Kai
Wang, Youpeng
Zhang, Yuanzheng
Sun, Hongfa
Zhang, Xuhui
Sun, Chuandong
Zhang, Bingyuan
Zhang, Ying
Cheng, Haoyue
Liu, Ao
Wang, Mengyao
Han, Bing
author_sort Ma, Kai
collection PubMed
description SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. We retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%, 56/72) patients, of which, the frequently mutated driver genes were TP53, KMT2D, KMT2C, BCOR, APC, BAP1, ARID1A, NF1, PIK3CA, KRAS, and LRP1B. Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domain which were associated with intercellular adhesion. We identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations, which provided potential targets for early diagnosis and treatment planning of CCA. ABSTRACT: The early diagnosis and treatment of cholangiocarcinoma (CCA) remain a challenge worldwide. Genetic testing promises to solve these problems. Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. Thus, we retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%) patients, of which, the frequently mutated driver genes were TP53 (27.78%), KMT2D (23.81%), KMT2C (20.63%), BCOR (18.06%), APC (15.28%), BAP1 (13.89%), ARID1A (12.50%), NF1 (12.50%), PIK3CA (12.50%), KRAS (11.11%), and LRP1B (11.11%). Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domains which were associated with intercellular adhesion. Based on cancer-related public databases and multiple protein function prediction algorithms, we identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations. Molecular analysis of tumors from a precision oncology perspective can provide potential targets for early diagnosis and treatment of CCA and assist physicians in clinical decision making.
format Online
Article
Text
id pubmed-9600135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96001352022-10-27 Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma Ma, Kai Wang, Youpeng Zhang, Yuanzheng Sun, Hongfa Zhang, Xuhui Sun, Chuandong Zhang, Bingyuan Zhang, Ying Cheng, Haoyue Liu, Ao Wang, Mengyao Han, Bing Cancers (Basel) Article SIMPLE SUMMARY: Genetic testing promises to provide guidance for early diagnosis and treatment of cholangiocarcinoma (CCA). Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. We retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%, 56/72) patients, of which, the frequently mutated driver genes were TP53, KMT2D, KMT2C, BCOR, APC, BAP1, ARID1A, NF1, PIK3CA, KRAS, and LRP1B. Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domain which were associated with intercellular adhesion. We identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations, which provided potential targets for early diagnosis and treatment planning of CCA. ABSTRACT: The early diagnosis and treatment of cholangiocarcinoma (CCA) remain a challenge worldwide. Genetic testing promises to solve these problems. Due to the different mutation landscapes across populations and the paucity of sequencing data of Chinese patients with CCA, the existing mutation landscape is insufficient to reflect the mutation characteristics of Chinese patients. Thus, we retrospectively analyzed 72 Chinese patients with CCA who had received genetic testing of targeted capture sequencing. A total of 2152 somatic mutations were detected in 56 (77.78%) patients, of which, the frequently mutated driver genes were TP53 (27.78%), KMT2D (23.81%), KMT2C (20.63%), BCOR (18.06%), APC (15.28%), BAP1 (13.89%), ARID1A (12.50%), NF1 (12.50%), PIK3CA (12.50%), KRAS (11.11%), and LRP1B (11.11%). Most mutations were enriched in NRF2, TP53, and TGF-Beta oncogenic signaling pathways and cadherin repeat domains which were associated with intercellular adhesion. Based on cancer-related public databases and multiple protein function prediction algorithms, we identified 118 novel pathogenic or likely pathogenic somatic mutations and 77 actionable alterations. Molecular analysis of tumors from a precision oncology perspective can provide potential targets for early diagnosis and treatment of CCA and assist physicians in clinical decision making. MDPI 2022-10-16 /pmc/articles/PMC9600135/ /pubmed/36291846 http://dx.doi.org/10.3390/cancers14205062 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ma, Kai
Wang, Youpeng
Zhang, Yuanzheng
Sun, Hongfa
Zhang, Xuhui
Sun, Chuandong
Zhang, Bingyuan
Zhang, Ying
Cheng, Haoyue
Liu, Ao
Wang, Mengyao
Han, Bing
Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title_full Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title_fullStr Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title_full_unstemmed Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title_short Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma
title_sort clinical practice of targeted capture sequencing to identify actionable alterations in cholangiocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600135/
https://www.ncbi.nlm.nih.gov/pubmed/36291846
http://dx.doi.org/10.3390/cancers14205062
work_keys_str_mv AT makai clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT wangyoupeng clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT zhangyuanzheng clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT sunhongfa clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT zhangxuhui clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT sunchuandong clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT zhangbingyuan clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT zhangying clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT chenghaoyue clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT liuao clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT wangmengyao clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma
AT hanbing clinicalpracticeoftargetedcapturesequencingtoidentifyactionablealterationsincholangiocarcinoma